妥布霉素地塞米松治疗睑板腺功能障碍的临床观察

发布时间：2018-10-21 16:20

【摘要】：目的:观察妥布霉素地塞米松治疗睑板腺功能障碍(MGD)的疗效和安全性。方法:108例MGD患者随机分为对照组(53例)和观察组(55例)。对照组患者给予常规物理清洁方式清理眼睑,同时饭后温水送服盐酸多西环素片0.1 g,每日2次。观察组患者在对照组治疗的基础上给予妥布霉素地塞米松眼膏长约1.0~1.5 cm,涂入结膜囊,每日4次。两组疗程均为4周。观察两组患者的临床疗效,治疗前后眼睑观察评分、症状评分、白细胞介素6(IL-6)和肿瘤坏死因子α(TNF-α)水平及不良反应发生情况。结果:观察组患者总有效率显著高于对照组(89.1%vs.77.4%),差异有统计学意义(P0.05)。治疗前,两组患者眼睑观察评分、症状评分、IL-6和TNF-α水平比较,差异均无统计学意义(P0.05)。治疗后,两组患者眼睑观察评分均显著高于同组治疗前,且观察组显著高于对照组;两组患者症状评分、IL-6和TNF-α水平均显著低于同组治疗前,且观察组显著低于对照组,差异均有统计学意义(P0.05)。两组患者不良反应发生率比较,差异无统计学意义(P0.05)。结论:在常规治疗的基础上给予妥布霉素地塞米松治疗MGD患者的疗效显著,可显著改善临床症状,且未增加不良反应的发生。
[Abstract]:Objective: to observe the efficacy and safety of tobramycin dexamethasone in the treatment of tarsal gland dysfunction (MGD). Methods: 108 patients with MGD were randomly divided into control group (53 cases) and observation group (55 cases). The patients in the control group were given routine physical cleaning method to clean the eyelids, and the warm water after meals was given 0.1 g doxycycline hydrochloride tablets twice a day. The patients in the observation group were treated with tobramycin dexamethasone eye ointment for 1.5 cm, and applied into the conjunctival sac 4 times a day. The course of treatment was 4 weeks in both groups. The clinical efficacy, eyelid score, symptom score, levels of interleukin 6 (IL-6) and tumor necrosis factor 伪 (TNF- 伪) and the incidence of adverse reactions were observed. Results: the total effective rate in the observation group was significantly higher than that in the control group (89.1vs.77.4%), and the difference was statistically significant (P0.05). Before treatment, there was no significant difference in eyelid observation score, symptom score, IL-6 and TNF- 伪 levels between the two groups (P0.05). After treatment, the eyelid observation scores of the two groups were significantly higher than those of the same group before treatment, and the observation group was significantly higher than the control group, and the symptom scores, IL-6 and TNF- 伪 levels of the two groups were significantly lower than those of the same group, and the observation group was significantly lower than the control group. The difference was statistically significant (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion: tobramycin dexamethasone is effective in the treatment of MGD patients on the basis of routine treatment. It can significantly improve clinical symptoms and does not increase the incidence of adverse reactions.
【作者单位】：新疆石河子大学第一附属医院眼科;
【分类号】：R777.1

【相似文献】